-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UhQbZWKw1q2LkWU62ur6HuFjcFUCYt7SLUlHw0OZPW8xl8o2Wu+6dLaPMm2I6eFE
 Xp36vAJB8qm8bpHLTfBsdw==

<SEC-DOCUMENT>0001102624-08-000031.txt : 20080207
<SEC-HEADER>0001102624-08-000031.hdr.sgml : 20080207
<ACCEPTANCE-DATETIME>20080207095308
ACCESSION NUMBER:		0001102624-08-000031
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080207
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080207
DATE AS OF CHANGE:		20080207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		08583338

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: February  07, 2008</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive, Portland, Maine</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>(207) 878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On February 7, 2008 ImmuCell Corporation (the "Company") issued a press release announcing its financial results for the three and twelve month periods ended December 31, 2007.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.  The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act ("the Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<br><b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated February  07, 2008</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table>
<tr>
<td width="50%" valign=top>
Dated: February  07, 2008<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated February  07, 2008</td>
</tr>
</table>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for 2007</b>
<p>PORTLAND, ME -- 02/07/2008 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and twelve month
periods ended December 31, 2007.
</p>
<p>
For the three-month period ended December 31, 2007, product sales increased
by 41%, or $430,000, to $1,490,000 in comparison to the same period in
2006.  For the year ended December 31, 2007, product sales increased by
11%, or $466,000, to $4,772,000 compared to the same period in 2006.
</p>
<p>
"Most of this growth came from export sales.  Sales of our lead product,
First Defense&#174;, increased by 64% and 16% during the three and twelve
month periods ended December 31, 2007, respectively," commented Michael F.
Brigham, President and CEO.  "The 16% annual growth is a result of our
efforts to increase product sales worldwide."
</p>
<p>
The Company reported income before income taxes of $115,000 during the
three-month period ended December 31, 2007 in comparison to $202,000 during
the same period in 2006.  This resulted in net income of $72,000 ($0.02 per
diluted share) during the three-month period ended December 31, 2007 in
comparison to $155,000 ($0.05 per diluted share) during the same period in
2006.  The Company reported income before income taxes of $1,144,000 during
the year ended December 31, 2007 compared to $1,034,000 during the same
period in 2006.  This resulted in net income of $662,000 ($0.22 per diluted
share) during the year ended December 31, 2007 compared to $647,000 ($0.21
per diluted share) during the same period in 2006.  During the third
quarter of 2007, the Company recorded a non-recurring net increase to
income before income taxes of approximately $602,000, with no impact on
cash, in connection with the termination of a product license.
</p>
<p>
Total product development expenses increased by 63%, or $167,000, during
the three-month period ended December 31, 2007 in comparison to the same
period in 2006, and these expenses increased by 64%, or $613,000, during
the year ended December 31, 2007 compared to the same period in 2006.
</p>
<p>
 "Excluding non-cash amortization expense related to an intangible
technology asset from both periods, product development expenses increased
by 53%, or $394,000, during the year ended December 31, 2007 compared to
the same period in 2006," added Mr. Brigham.
</p>
<p>
Cash, cash equivalents and short-term investments decreased by 18%, or
$1,202,000, to $5,412,000 at December 31, 2007 as compared to $6,614,000 at
December 31, 2006.  The decrease was largely due to an investment made in
our facility in connection with an ongoing effort to become compliant with
current Good Manufacturing Practices (cGMP) regulations.  Stockholders'
equity increased by 8%, or $725,000, to $10,057,000 at December 31, 2007 as
compared to $9,332,000 at December 31, 2006.  The Company had 2,892,000
shares of common stock outstanding as of December 31, 2007.
</p>
<p>
<pre>
                                        (Unaudited)        (Unaudited)
                                    Three Months Ended  Twelve Months Ended
                                       December 31,        December 31,
                                    ------------------- -------------------
(In thousands, except per share        2007      2006      2007      2006
 amounts)                           --------- --------- --------- ---------

Revenues:
Product Sales                       $   1,490 $   1,060 $   4,772 $   4,306
Other Revenues                             13       163     1,297       495
                                    --------- --------- --------- ---------
Total Revenues                          1,503     1,223     6,069     4,801

Cost and expenses:
Product costs                             651       521     2,269     1,882
Product development expenses              430       264     1,579       966
Selling, general and administrative
 expenses                                 365       310     1,349     1,182
                                    --------- --------- --------- ---------
Total costs and expenses                1,446     1,095     5,197     4,030
                                    --------- --------- --------- ---------

Net operating income                       57       128       872       771

Interest and other income                  58        74       272       263
                                    --------- --------- --------- ---------

Income before income taxes                115       202     1,144     1,034
Income tax expense                         43        47       482       387
                                    --------- --------- --------- ---------
Net income                          $      72 $     155 $     662 $     647
                                    ========= ========= ========= =========

Net income per common share:
Basic                               $    0.02 $    0.05 $    0.23 $    0.22
Diluted                             $    0.02 $    0.05 $    0.22 $    0.21

Weighted average common shares
 outstanding:
Basic                                   2,892     2,897     2,897     2,888
Diluted                                 2,990     3,061     3,034     3,051





                                                               (Unaudited)
                                                  At December  At December
(In thousands)                                      31, 2006     31, 2007
                                                  ------------ ------------
Cash, cash equivalents and short-term investments $      6,614 $      5,412
Total assets                                            11,364       10,412
Net working capital                                      6,934        6,710
Stockholders&#146; equity                              $      9,332 $     10,057
</pre>
</p>
<p>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
